BioLineRx (BLRX) Tops Q2 EPS by 7c

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance
• Generac Holdings (GNRC) PT Raised to $335 at UBS on durability and visibility of earnings trajectory